The clinical safety of high-dose piracetam - Its use in the treatment of acute stroke

Pharmacopsychiatry

Volumn 32, Issue SUPPL. 1, 1999, Pages 33-37

  De Reuck, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT; PIRACETAM;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PIRACETAM; STATISTICS; TREATMENT OUTCOME;

EID: 0033089030     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979234     Document Type: Article

References (2)

1. Abuhazzabab Sr. FS. Merwin GE, Zimmermann RL, Sherman MC: A double-blind investigation of piracetam (Nootropil) in the memory of geriatric inpatients. Psychopharmacol Bull 1978; 14: 23-26.
2. Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salina M, Waegemans T, Marsden CD: Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8: 63-68.